Kim MH, et al. - Among 2,729 patients who had surgery for breast cancer, researchers compared postoperative recurrence-free survival and overall survival between those who received perioperative dexamethasone vs those who did not. Medical records, as well as follow-up findings until December 2015, were analyzed. Based on the receipt or non-receipt of a single dose of intravenous dexamethasone perioperatively, patients were defined. Cox regression analyses were also carried out. They adjusted for selection bias via a sensitivity test with propensity score matching. Of 2,628 patients, perioperative dexamethasone was received by 236 (8.5%). In breast cancer patients, findings revealed no link between a perioperative single dose of dexamethasone and increased recurrence or mortality following curative surgery.